PET/CT: Advancing Early Cancer Detection and Outcomes
*Corresponding Author: Melissa Grant, Northshore Institute of Oncology, USA, Email: mgrant@northshoreoncology.orgReceived Date: Sep 01, 2025 / Accepted Date: Sep 29, 2025 / Published Date: Sep 29, 2025
Citation: Grant M (2025) PET/CT: Advancing Early Cancer Detection and Outcomes. jcd 09: 321.DOI: 10.4172/2476-2253.1000321
Copyright: © 2025 Melissa Grant This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
PET/CT imaging is crucial for early cancer detection across diverse malignancies. Studies highlight its effectiveness in whole
body screening for asymptomatic cancers, improving diagnostic performance for hepatocellular, lung, and prostate cancers. It also
demonstrates superior sensitivity in detecting recurrent head and neck, breast, and gastric cancers. FDG-PET/CT offers proactive
screening for high-risk individuals with germline PTEN pathogenic variants and shows promise for early pancreatic cancer detection.
Novel PET imaging biomarkers further enhance the ability to identify breast lesions at initial stages, collectively advancing early
intervention and patient outcomes.
